source
- Capricor Therapeutics receives second FDA rejection for Duchenne cell therapy deramiocelThe U.S. Food and Drug Administration issued a second complete response letter rejecting Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy. The agency said the data did…
- FDA again turns back Capricor Duchenne cell therapyIn an unusual statement, the FDA accused Capricor of “serious data integrity violations” that compromised its study findings and led to deramiocel’s second rejection since 2025.BioPharma Dive · 1h ago↗ source